Expansion and uncertainty around GLP-1 obesity treatment

Medicare's low-cost obesity-drug program is reportedly generating about 200,000 prescriptions, signaling substantial demand while leaving questions about eligibility, long-term outcomes, side effects, equity, and total costs. New mouse research on persistent obesity-related changes in adipose-tissue macrophages offers a possible biological explanation for weight regain, but combination therapies, broader metabolic uses, and the obesity-memory mechanism remain investigational.